Skip to main content
Fig. 3 | Clinical Epigenetics

Fig. 3

From: Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

Fig. 3

Prognostic performance of circulating NPTX2 methylation in comparison with other circulating tumor biomarkers in mPDAC patients. Receiving operating characteristic (ROC) curves of plasma RAS MAF, CA19-9, cfDNA concentration and NPTX2 methylation in the prognosis of mPDAC. The higher prognostic value was observed for NPTX2 methylation levels (AUC 0.80, 95% CI 0.66–0.84)

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us